GSK plc Form 6-K: Report of foreign private issuer
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2015-12-23: Form 6-K; Period of report 2015-12-23; Description DIRECTORATE CHANGE; Document gsk201512236k.htm.
- 2015-12-21: Form 6-K; Period of report 2015-12-21; Description COMPLETION OF DIVESTMENT OF RIGHTS TO OFATUMUMAB; Document gsk201512216k.htm.
- 2015-12-18: Form 6-K; Period of report 2015-12-18; Description DIRECTOR/PDMR SHAREHOLDING; Document gsk201512186k2.htm.
- 2015-12-18: Form 6-K; Period of report 2015-12-18; Description VIIV HEALTHCARE TO ACQUIRE BMS R&D HIV ASSETS; Document gsk201512186k.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2015-12-23 | 6-K | 2015-12-23 | DIRECTORATE CHANGE | gsk201512236k.htm |
| 2015-12-21 | 6-K | 2015-12-21 | COMPLETION OF DIVESTMENT OF RIGHTS TO OFATUMUMAB | gsk201512216k.htm |
| 2015-12-18 | 6-K | 2015-12-18 | DIRECTOR/PDMR SHAREHOLDING | gsk201512186k2.htm |
| 2015-12-18 | 6-K | 2015-12-18 | VIIV HEALTHCARE TO ACQUIRE BMS R&D HIV ASSETS | gsk201512186k.htm |
| 2015-12-16 | 6-K | 2015-12-16 | POSITIVE RESULTS FROM SIRUKUMAB PHIII PROGRAMME | gsk201512166k.htm |
| 2015-12-10 | 6-K | 2015-12-10 | DIRECTOR/PDMR SHAREHOLDING | gsk201512106k2.htm |
| 2015-12-10 | 6-K | 2015-12-10 | BOARD COMMITTEE CHANGES | gsk201512106k.htm |
| 2015-12-02 | 6-K | 2015-12-01 | NUCALA EUROPEAN MARKETING AUTHORISATION RECEIVED | gsk201512026k.htm |
| 2015-12-01 | 6-K | 2015-12-01 | DIRECTOR/PDMR SHAREHOLDING | gsk201512016k2.htm |
| 2015-12-01 | 6-K | 2015-12-01 | TOTAL VOTING RIGHTS | gsk201512016k.htm |
| 2015-11-13 | 6-K | 2015-11-13 | DIRECTOR/PDMR SHAREHOLDING | gsk201511136k.htm |
| 2015-11-12 | 6-K | 2015-11-12 | BLOCKLISTING INTERIM REVIEW | gsk201511126k.htm |
| 2015-11-12 | 6-K | 2015-11-12 | DIRECTOR/PDMR SHAREHOLDING | gsk201511116k.htm |
| 2015-11-05 | 6-K | 2015-11-04 | GSK?S NUCALA? RECEIVES APPROVAL FROM US FDA | gsk201511046k.htm |
| 2015-11-03 | 6-K | 2015-11-03 | GSK PROFILES INNOVATIVE R&D PORTFOLIO TO INVESTORS | gsk201511036k2.htm |
| 2015-11-03 | 6-K | 2015-11-03 | VIIV HEALTHCARE ANNOUNCES POSITIVE RESULTS | gsk201511036k.htm |
| 2015-11-02 | 6-K | 2015-11-02 | DIRECTOR DECLARATION | gsk201511026k2.htm |
| 2015-11-02 | 6-K | 2015-11-02 | TOTAL VOTING RIGHTS | gsk201511026k.htm |
| 2015-10-29 | 6-K | 2015-10-29 | DIRECTOR/PDMR SHAREHOLDING | gsk201510296k.htm |
| 2015-10-28 | 6-K | 2015-10-28 | 3RD QUARTER RESULTS | gsk201510286k.htm |
| 2015-10-27 | 6-K | 2015-10-27 | RESULTS OF LABA SAFETY STUDY FOR ADVAIR DISKUS | gsk201510276k2.htm |
| 2015-10-27 | 6-K | 2015-10-27 | 90% EFFICACY IN SHINGLES VACCINE FOR OVER 70'S | gsk201510276k.htm |
| 2015-10-20 | 6-K | 2015-10-20 | DIRECTOR/PDMR SHAREHOLDING | gsk201510206k5.htm |
| 2015-10-20 | 6-K | 2015-10-20 | DIRECTOR/PDMR SHAREHOLDING | gsk201510206k4.htm |
| 2015-10-20 | 6-K | 2015-10-20 | DIRECTOR/PDMR SHAREHOLDING | gsk201510206k3.htm |
| 2015-10-20 | 6-K | 2015-10-20 | DIRECTOR/PDMR SHAREHOLDING | gsk201510206k2.htm |
| 2015-10-20 | 6-K | 2015-10-20 | POSITIVE DATA FOR INCRUSE ELLIPTA COMPARISONS | gsk201510206k.htm |
| 2015-10-19 | 6-K | 2015-10-19 | DIRECTOR/PDMR SHAREHOLDING | gsk201510196k3.htm |
| 2015-10-19 | 6-K | 2015-10-19 | DIRECTOR/PDMR SHAREHOLDING | gsk201510196k2.htm |
| 2015-10-19 | 6-K | 2015-10-19 | DIRECTOR/PDMR SHAREHOLDING | gsk201510196k.htm |
| 2015-10-13 | 6-K | 2015-10-13 | DIRECTOR/PDMR SHAREHOLDING | gsk201510136k.htm |
| 2015-10-13 | 6-K | 2015-10-12 | DIRECTOR/PDMR SHAREHOLDING | gsk201510126k.htm |
| 2015-10-08 | 6-K | 2015-10-08 | DIRECTOR/PDMR SHAREHOLDING | gsk201510086k.htm |
| 2015-10-07 | 6-K | 2015-10-07 | DIRECTOR/PDMR SHAREHOLDING | gsk201510076k.htm |
| 2015-10-05 | 6-K | 2015-10-05 | DIRECTOR/PDMR SHAREHOLDING | gsk201510056k.htm |
| 2015-10-02 | 6-K | 2015-10-02 | DIRECTOR/PDMR SHAREHOLDING | gsk201510026k2.htm |
| 2015-10-02 | 6-K | 2015-10-02 | DIRECTOR/PDMR SHAREHOLDING | gsk201510026k.htm |
| 2015-10-01 | 6-K | 2015-10-01 | DIRECTOR/PDMR SHAREHOLDING | gsk201510016k2.htm |
| 2015-10-01 | 6-K/A | 2015-10-01 | TOTAL VOTING RIGHTS | gsk201510016k.htm |
| 2015-09-30 | 6-K | 2015-09-30 | DIRECTOR/PDMR SHAREHOLDING | gsk201509306k.htm |
| 2015-09-28 | 6-K | 2015-09-28 | DIRECTOR/PDMR SHAREHOLDING | gsk201509286k.htm |
| 2015-09-24 | 6-K | 2015-09-24 | CHMP OPINION FOR MEPOLIZUMAB (NUCALA) IN EUROPE | gsk201509246k2.htm |
| 2015-09-24 | 6-K | 2015-09-24 | INTENTION TO FILE RELVAR ELLIPTA FOR COPD IN JAPAN | gsk201509246k.htm |
| 2015-09-23 | 6-K | 2015-09-23 | VIIV HEALTHCARE PHASE LLLB/IV STRIIVING DATA | gsk201509236k.htm |
| 2015-09-17 | 6-K | 2015-09-17 | DIRECTOR/PDMR SHAREHOLDING | gsk201509176k.htm |
| 2015-09-14 | 6-K | 2015-09-14 | DIRECTOR/PDMR SHAREHOLDING | gsk201509146k.htm |
| 2015-09-10 | 6-K | 2015-09-10 | DIRECTOR/PDMR SHAREHOLDING | gsk201509106k.htm |
| 2015-09-08 | 6-K | 2015-09-08 | RESULTS FROM THE SUMMIT COPD CV SURVIVAL STUDY | gsk201509086k.htm |
| 2015-09-01 | 6-K | 2015-09-01 | TOTAL VOTING RIGHTS | gsk201509016k.htm |
| 2015-09-01 | 6-K | 2015-09-01 | DIRECTOR/PDMR SHAREHOLDING | gsk201509016k1.htm |
| 2015-09-01 | 6-K | 2015-09-01 | DIRECTOR/PDMR SHAREHOLDING | gsk201509016k2.htm |
| 2015-08-28 | 6-K | 2015-08-28 | DIRECTOR/PDMR SHAREHOLDING | gsk201508286k.htm |
| 2015-08-27 | 6-K | 2015-08-27 | DIRECTOR/PDMR SHAREHOLDING | gsk201508276k.htm |
| 2015-08-21 | 6-K | 2015-08-21 | GSK TO DIVEST OFATUMUMAB - AUTO-IMMUNE INDICATIONS | gsk20150821.htm |
| 2015-08-14 | 6-K | 2015-08-14 | DIRECTOR/PDMR SHAREHOLDING | gsk201508146k.htm |
| 2015-08-12 | 6-K | 2015-08-12 | DIRECTOR/PDMR SHAREHOLDING | gsk201508126k.htm |
| 2015-08-05 | 6-K | 2015-08-05 | DIRECTOR/PDMR SHAREHOLDING | gsk201508056k.htm |
| 2015-08-03 | 6-K | 2015-08-03 | DIRECTOR/PDMR SHAREHOLDING | gsk201508036k3.htm |
| 2015-08-03 | 6-K | 2015-08-03 | DIRECTOR/PDMR SHAREHOLDING | gsk201508036k2.htm |
| 2015-08-03 | 6-K | 2015-08-03 | TOTAL VOTING RIGHTS | gsk201508036k.htm |
| 2015-07-31 | 6-K | 2015-07-31 | ADJUSTED FREE CASH FLOW PERFORMANCE MEASURE | gsk201507316k.htm |
| 2015-07-29 | 6-K | 2015-07-29 | HALF YEARLY REPORT | gsk201507296k.htm |
| 2015-07-27 | 6-K | 2015-07-27 | DIRECTOR/PDMR SHAREHOLDING | gsk201507276k1.htm |
| 2015-07-27 | 6-K | 2015-07-27 | DIRECTOR/PDMR SHAREHOLDING | gsk201507276k.htm |
| 2015-07-24 | 6-K | 2015-07-24 | DIRECTOR/PDMR SHAREHOLDING | gsk201507246k4.htm |
| 2015-07-24 | 6-K | 2015-07-24 | DIRECTOR/PDMR SHAREHOLDING | gsk201507246k3.htm |
| 2015-07-24 | 6-K | 2015-07-24 | DIRECTOR/PDMR SHAREHOLDING | gsk201507246k2.htm |
| 2015-07-24 | 6-K | 2015-07-24 | DIRECTOR/PDMR SHAREHOLDING | gsk201507246k.htm |
| 2015-07-21 | 6-K | 2015-07-21 | DIRECTOR/PDMR SHAREHOLDING | gsk201507216k.htm |
| 2015-07-20 | 6-K | 2015-07-20 | DIRECTOR/PDMR SHAREHOLDING | gsk201507206k1.htm |
| 2015-07-20 | 6-K | 2015-07-20 | DIRECTOR/PDMR SHAREHOLDING | gsk201507206k2.htm |
| 2015-07-20 | 6-K | 2015-07-20 | DIRECTOR/PDMR SHAREHOLDING | gsk201507206k.htm |
| 2015-07-10 | 6-K | 2015-07-10 | DIRECTOR/PDMR SHAREHOLDING | gsk201507106k3.htm |
| 2015-07-10 | 6-K | 2015-07-10 | DIRECTOR/PDMR SHAREHOLDING | gsk201507106k2.htm |
| 2015-07-10 | 6-K | 2015-07-10 | DIRECTOR/PDMR SHAREHOLDING | gsk201507106k1.htm |
| 2015-07-10 | 6-K | 2015-07-10 | DIRECTOR/PDMR SHAREHOLDING | gsk201507106k.htm |
| 2015-07-07 | 6-K | 2015-07-07 | DIRECTOR/PDMR SHAREHOLDING | gsk201507076k.htm |
| 2015-07-01 | 6-K | 2015-07-01 | DIRECTOR/PDMR SHAREHOLDING | gsk201507016k1.htm |
| 2015-07-01 | 6-K | 2015-07-01 | DIRECTOR/PDMR SHAREHOLDING | gsk201507016k2.htm |
| 2015-07-01 | 6-K | 2015-07-01 | TOTAL VOTING RIGHTS | gsk201507016k.htm |
| 2015-06-24 | 6-K | 2015-06-24 | DIRECTOR/PDMR SHAREHOLDING | gsk201506246k.htm |
| 2015-06-22 | 6-K | 2015-06-22 | REGULATORY UPDATE - SALE OF NIMENRIX AND MENCEVAX | gsk201506226k.htm |
| 2015-06-11 | 6-K | 2015-06-11 | US FDA ADVISORY COMMITTEE ON MEPOLIZUMAB | gsk201506116k2.htm |
| 2015-06-11 | 6-K | 2015-06-11 | BLOCKLISTING APPLICATION | gsk201506116k.htm |
| 2015-06-10 | 6-K | 2015-06-10 | DIRECTOR/PDMR SHAREHOLDING | gsk201506106k.htm |
| 2015-06-09 | 6-K | 2015-06-09 | DIRECTOR/PDMR SHAREHOLDING | gsk201506096k.htm |
| 2015-06-01 | 6-K | 2015-06-01 | TOTAL VOTING RIGHTS | gsk201506016k.htm |
| 2015-05-28 | 6-K/A | 2015-05-28 | DIRECTOR/PDMR SHAREHOLDING - REPLACEMENT | gsk201505286ka.htm |
| 2015-05-26 | 6-K | 2015-05-26 | DIRECTOR/PDMR SHAREHOLDING | gsk201505266k.htm |
| 2015-05-22 | 6-K | 2015-05-22 | DIRECTOR/PDMR SHAREHOLDING | gsk201505226k2.htm |
| 2015-05-22 | 6-K | 2015-05-22 | BLOCKLISTING INTERIM REVIEW | gsk201505226k.htm |
| 2015-05-15 | 6-K | 2015-05-15 | DIRECTOR/PDMR SHAREHOLDING | gsk201505156k3.htm |
| 2015-05-15 | 6-K | 2015-05-15 | DIRECTOR/PDMR SHAREHOLDING | gsk201505156k2.htm |
| 2015-05-15 | 6-K | 2015-05-15 | DIRECTOR/PDMR SHAREHOLDING | gsk201505156k.htm |
| 2015-05-13 | 6-K | 2015-05-13 | DIRECTOR/PDMR SHAREHOLDING | gsk201505136k.htm |
| 2015-05-12 | 6-K | 2015-05-08 | DIRECTOR/PDMR SHAREHOLDING | gsk201505126k1.htm |
| 2015-05-12 | 6-K | 2015-05-08 | DIRECTOR/PDMR SHAREHOLDING | gsk201505126k.htm |
| 2015-05-11 | 6-K | 2015-05-07 | DIRECTOR/PDMR SHAREHOLDING | gsk201505116k1.htm |
| 2015-05-11 | 6-K | 2015-05-11 | DIRECTOR/PDMR SHAREHOLDING | gsk201505116k.htm |
| 2015-05-08 | 6-K | 2015-05-07 | RESULT OF AGM | gsk201505076k2.htm |